GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Current Deferred Revenue

Spectral AI (Spectral AI) Current Deferred Revenue : $2.18 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Spectral AI's current deferred revenue for the quarter that ended in Mar. 2024 was $2.18 Mil.

Spectral AI Current Deferred Revenue Historical Data

The historical data trend for Spectral AI's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectral AI Current Deferred Revenue Chart

Spectral AI Annual Data
Trend Dec21 Dec22 Dec23
Current Deferred Revenue
0.02 - 2.31

Spectral AI Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Current Deferred Revenue Get a 7-Day Free Trial - - 0.80 2.31 2.18

Spectral AI Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Spectral AI's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectral AI (Spectral AI) Business Description

Traded in Other Exchanges
N/A
Address
2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.
Executives
John Michael Dimaio 10 percent owner 6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p. 10 percent owner 2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton director RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b. director 13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher officer: Chief Scientist 6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler officer: Chief Financial Officer 8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan director, officer: CHIEF EXECUTIVE OFFICER 3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone officer: GENERAL COUNSEL 1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos officer: CHIEF OPERATING OFFICER 5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai director 10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr. director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc director 767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg 10 percent owner 73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260